SR90107A/ORG31540: Phase II; Phase III

In a dose-ranging Phase II study of SR90107A in 593 patients undergoing total hip replacement, SR90107A given at once

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE